Clinical Trials Browser

OTHER × Malignant mesenchymal tumor × Irinotecan × Clear all

NCT00077285 2025-11-04

Irinotecan and Carboplatin as Upfront Window Therapy in Treating Patients With Newly Diagnosed Intermediate-Risk or High-Risk Rhabdomyosarcoma

Phase 2 Active not recruiting

Malignant mesenchymal tumor, Rhabdomyosarcoma, Sarcoma